A prospective, single centre trial to evaluate the safety and efficacy of enzalutamide (Xtandi ®) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel plus prednisone

Trial Profile

A prospective, single centre trial to evaluate the safety and efficacy of enzalutamide (Xtandi ®) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel plus prednisone

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2017 New trial record
    • 01 Mar 2017 Primary endpoint has been met. (reduction in serum prostate-specific antigen (PSA)) as per results published in the Anticancer Research.
    • 01 Mar 2017 Results published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top